Prevention by a somatostatin analogue of the hypertensive and cardiovascular structural changes induced by blockade of adenosine receptors.
Calhau C, Martel F, Alçada MN, Azevedo I.
Calhau C, et al. Among authors: azevedo i.
J Auton Pharmacol. 1997 Aug;17(4):243-7. doi: 10.1046/j.1365-2680.1997.00459.x.
J Auton Pharmacol. 1997.
PMID: 9373783
Long-term administration of the adenosine receptor antagonist, 1,3-dipropyl-8-sulfophenylxanthine (DPSPX), causes arterial hypertension and cardiovascular hypertrophic and hyperplastic changes (Matias, Albino-Teixeira, Polonia & Azevedo, 1991). As somatostatin is a rep …
Long-term administration of the adenosine receptor antagonist, 1,3-dipropyl-8-sulfophenylxanthine (DPSPX), causes arterial hypertension and …